Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease
- 15 patients dosed with RTX001, an engineered Regenerative Macrophage Therapy designed to address inflammation and fibrosis
- EMERALD is evaluating safety and efficacy of RTX001 in patients with end-stage liver disease and a history of decompensated liver cirrhosis
- Interim clinical data expected in Q4 2026
Edinburgh and London, UK, 11 September 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced that the final patient has been treated in EMERALD, the Company’s Phase I/II clinical trial evaluating its engineered RMT, RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis. Interim data are expected in the fourth quarter of 2026.
